Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Cytarabine + Daunorubicin + Pinometostat |
Synonyms | |
Therapy Description |
EPZ-5676 (Pinometostat) inhibits DOT1L histone methyltransferase activity, resulting in decreased growth of leukemia cells with MLL rearrangements (PMID: 23801631, PMID: 26645404). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cytarabine | Cytosar-U | Ara-C | Cytosar-U (cytarabine) is a cytidine analog that, when incorporated into DNA, inhibits DNA synthesis and repair (PMID: 32524309). | |
Daunorubicin | Cerubidine | Rubidomycin|daunomycin hydrochloride|rubomycin C|Acetyladriamycin | Chemotherapy - Anthracycline 13 | Cerubidine (daunorubicin) is an anthracycline, which inhibits DNA replication and repair. Cerubidine (daunorubicin) is FDA approved for AML and MLL (FDA.gov). |
Pinometostat | EPZ-5676|EPZ5676 | DOT1L Inhibitor 3 | Pinometostat (EPZ-5676) inhibits DOT1L histone methyltransferase activity, resulting in decreased growth of leukemia cells with MLL rearrangements (PMID: 23801631, PMID: 26645404, PMID: 29724899). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03724084 | Phase Ib/II | Cytarabine + Daunorubicin + Pinometostat | Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement | Terminated | USA | 0 |